Chinese experts published in a top international medical journal: "Dual targeting and dual therapy" shows promising results for BRAF-mutant colorectal cancer.

On November 20, it was learned from the Second Affiliated Hospital of the Naval Medical University that the international top journal "British Medical Journal" published online on November 19th the latest research paper by Professor Zang Yuansheng and Professor Qin Baodong from the oncology department of the hospital, titled "Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis." The team led by Zang Yuansheng stated that this study conducted a comprehensive and in-depth investigation of treatment options for BRAF-mutated colorectal cancer, providing key evidence for breakthroughs in the efficacy of treatment for these patients. The study confirmed that EGFR/BRAF dual-targeted therapy is the cornerstone of treatment for BRAF mutation colorectal cancer. The "dual-target dual chemotherapy" regimen demonstrated excellent treatment effectiveness and controllable safety in systematic evaluations, and has been confirmed as the first choice for this difficult-to-treat population of colorectal cancer patients.